Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0D8KQ
|
|||
| Drug Name |
Jakafi
|
|||
| Synonyms |
Ruxolitinib phosphate; 1092939-17-7; Ruxolitinib (phosphate); Jakavi; (R)-3-(4-(7H-Pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphate; UNII-436LRU32H5; Ruxolitinib phosphate salt; Ruxolitinib phosphate(INCB018424); CHEBI:66917; 436LRU32H5; J-501793; (betaR)-beta-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazole-1-propanenitrile phosphate; (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile phosphate; Ruxolitinib phosphate [USAN]; Jaka
Click to Show/Hide
|
|||
| Indication | Essential thrombocythemia [ICD-11: 3B63.1Z; ICD-9: 238.71, 289.9] | Phase 3 | [1] | |
| Company |
Incyte, Wilmington, DE
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C17H21N6O4P
|
|||
| Canonical SMILES |
C1CCC(C1)C(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3.OP(=O)(O)O
|
|||
| InChI |
1S/C17H18N6.H3O4P/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16;1-5(2,3)4/h6,8-12,15H,1-5H2,(H,19,20,21);(H3,1,2,3,4)/t15-;/m1./s1
|
|||
| InChIKey |
JFMWPOCYMYGEDM-XFULWGLBSA-N
|
|||
| CAS Number |
CAS 1092939-17-7
|
|||
| PubChem Compound ID | ||||
| ChEBI ID |
CHEBI:66917
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.